Search
Search Results
-
PHF6 loss reduces leukemia stem cell activity in an acute myeloid leukemia mouse model
Acute myeloid leukemia (AML) is a malignant hematologic disease caused by gene mutations and genomic rearrangements in hematologic progenitors. The...
-
-
JAK/STAT in leukemia: a clinical update
Over the past three decades, considerable efforts have been expended on understanding the Janus kinase/signal transducer and activator of...
-
The circadian clock circuitry modulates leukemia initiating cell activity in T-cell acute lymphoblastic leukemia
BackgroundT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy, characterized by restricted cellular subsets with...
-
FDA-approved disulfiram as a novel treatment for aggressive leukemia
AbstractAcute leukemia continues to be a major cause of death from disease worldwide and current chemotherapeutic agents are associated with...
-
-
Proteomic profiling reveals ACSS2 facilitating metabolic support in acute myeloid leukemia
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by genomic aberrations in oncogenes, cytogenetic abnormalities, and an aberrant...
-
NOTCH1-Induced T-Cell Acute Lymphoblastic Leukemia In Vivo Models
T-cell acute lymphoblastic leukemia (T-ALL) is primarily a NOTCH1-driven disease, which represents approximately 15% of pediatric and 25% of adult...
-
-
Anti-leukemia effects of omipalisib in acute myeloid leukemia: inhibition of PI3K/AKT/mTOR signaling and suppression of mitochondrial biogenesis
Omipalisib (GSK2126458), a potent dual PI3K/mTOR inhibitor, is reported to exhibit anti-tumor effect in several kinds of cancers. More than 50% of...
-
Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
In BCR-ABL1 lymphoblastic leukemia, treatment heterogeneity to tyrosine kinase inhibitors (TKIs), especially in the absence of kinase domain...
-
UBE2C promotes the proliferation of acute myeloid leukemia cells through PI3K/AKT activation
This study aims to investigate the role and mechanism of tubiquitin-conjugating enzyme E2 C (UBE2C) in acute myeloid leukemia (AML). Initially, UBE2C...
-
Influencing factors of anthracycline-induced subclinical cardiotoxicity in acute leukemia patients
BackgroundCurrent treatment of acute leukemia is based on anthracycline chemotherapy. Anthracyclines, despite improving patient survival, have...
-
-
Biogenesis of Mitochondria in Multipotent Mesenchymal Stromal Cells in Patients with Acute Leukemia
In patients with acute leukemia, not only normal hematopoiesis, but also bone marrow stromal microenvironment is damaged. Multipotent mesenchymal...
-
Evaluation of Serum Paraoxonase, Myeloperoxidase, and HDL-Cholesterol Levels in Acute Myeloid Leukemia
Inflammation and oxidative stress play a significant role in the pathogenesis of acute myeloid leukemia. While myeloperoxidase carries pro-oxidant...
-
CADM1 impairs the effect of miR-1246 on promoting cell cycle progression in chemo-resistant leukemia cells
The interruption of normal cell cycle execution acts as an important part to the development of leukemia. It was reported that microRNAs (miRNAs)...
-
Endothelial-derived small extracellular vesicles support B-cell acute lymphoblastic leukemia development
PurposeThe bone marrow niche plays an important role in leukemia development. However, the contributions of different niche components to leukemia...
-
Immunotherapy for Acute Leukemia
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), particularly in the relapsed or refractory settings, traditionally associate...
-
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
Classifications of acute myeloid leukemia (AML) patients rely on morphologic, cytogenetic, and molecular features. Here we have established a novel...
